Odin P - Search Results

1

Reimers A, Odin P, Ljung H. Reimers A, et al. Drug Saf. 2025 Apr;48(4):339-361. doi: 10.1007/s40264-024-01506-5. Epub 2024 Dec 24. Drug Saf. 2025. PMID: 39718691 Free PMC article. Review.

2

Authors' reply to Chaker Ben Salem's comment on: "Drug-Induced Cognitive Impairment".

Reimers A, Odin P, Ljung H. Reimers A, et al. Drug Saf. 2025 Jul;48(7):841. doi: 10.1007/s40264-025-01568-z. Epub 2025 Jun 7. Drug Saf. 2025. PMID: 40481936 No abstract available.

3

Personality Trait Changes After Device-Aided Therapy: Insights From Parkinson's Patients and Their Close Relatives.

Scharfenort M, Hernström V, Rosqvist K, Ljung H, Nilsson MH, Odin P. Scharfenort M, et al. Parkinsons Dis. 2025 Jul 25;2025:6681692. doi: 10.1155/padi/6681692. eCollection 2025. Parkinsons Dis. 2025. PMID: 40756897 Free PMC article.

4

Factors associated with self-rated health in people with late-stage parkinson's and cognitive impairment.

Pigott JS, Armstrong M, Davies N, Davis D, Bloem BR, Lorenzl S, Meissner WG, Odin P, Ferreira JJ, Dodel R, Schrag A. Pigott JS, et al. Qual Life Res. 2024 Sep;33(9):2439-2452. doi: 10.1007/s11136-024-03703-2. Epub 2024 Jun 18. Qual Life Res. 2024. PMID: 38888672 Free PMC article.

5

Navigating the therapeutic landscape in advanced Parkinson's disease: a comprehensive review from infusion therapies to stem cells.

Fogliano C, Rigon L, Chaudhuri KR, Popławska-Domaszewicz K, Falup-Pecurariu C, Murasan I, Guerra A, Garon M, Odin P, Hattori N, Antonini A. Fogliano C, et al. Expert Opin Drug Deliv. 2025 Oct;22(10):1599-1616. doi: 10.1080/17425247.2025.2539962. Epub 2025 Aug 1. Expert Opin Drug Deliv. 2025. PMID: 40734379 Review.

6

Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease.

Rosqvist K, Odin P. Rosqvist K, et al. Parkinsons Dis. 2023 Oct 10;2023:6667339. doi: 10.1155/2023/6667339. eCollection 2023. Parkinsons Dis. 2023. PMID: 37854895 Free PMC article.

7

Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease.

Cenci MA, Ohlin KE, Odin P. Cenci MA, et al. CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):670-84. doi: 10.2174/187152711797247885. CNS Neurol Disord Drug Targets. 2011. PMID: 21838677 Review.

8

Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?

Timpka J, Henriksen T, Odin P. Timpka J, et al. Mov Disord Clin Pract. 2016 Mar 24;3(3):221-229. doi: 10.1002/mdc3.12303. eCollection 2016 May-Jun. Mov Disord Clin Pract. 2016. PMID: 30363573 Free PMC article. Review.

9

Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinson's Disease Patients.

Janz C, Timpka J, Rosqvist K, Paul G, Storch A, Odin P. Janz C, et al. J Parkinsons Dis. 2024;14(2):297-312. doi: 10.3233/JPD-230263. J Parkinsons Dis. 2024. PMID: 38217612 Free PMC article.

10

Recognition, management, and patient perspectives of impulsive-compulsive disorders in Parkinson's disease.

Wolfschlag M, Cedergren Weber G, Timpka J, Weintraub D, Odin P, Håkansson A. Wolfschlag M, et al. J Parkinsons Dis. 2025 May;15(3):585-594. doi: 10.1177/1877718X251323922. Epub 2025 Mar 16. J Parkinsons Dis. 2025. PMID: 40091420 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters